0000899243-21-008447.txt : 20210226
0000899243-21-008447.hdr.sgml : 20210226
20210226174731
ACCESSION NUMBER: 0000899243-21-008447
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210224
FILED AS OF DATE: 20210226
DATE AS OF CHANGE: 20210226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gordon Gary B.
CENTRAL INDEX KEY: 0001811354
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39279
FILM NUMBER: 21691882
MAIL ADDRESS:
STREET 1: C/O AYALA PHARMACEUTICALS, INC.
STREET 2: OPPENHEIMER 4
CITY: REHOVOT
STATE: L3
ZIP: 7670104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001797336
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823578375
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1313 N. MARKET STREET
STREET 2: SUITE 5100
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: (857) 444-0553
MAIL ADDRESS:
STREET 1: 1313 N. MARKET STREET
STREET 2: SUITE 5100
CITY: WILMINGTON
STATE: DE
ZIP: 19801
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-24
0
0001797336
Ayala Pharmaceuticals, Inc.
AYLA
0001811354
Gordon Gary B.
OPPENHEIMER 4
REHOVOT
L3
7670104
ISRAEL
0
1
0
0
Chief Medical Officer
Common Stock
2021-02-24
4
M
0
3000
5.16
A
11520
D
Common Stock
2021-02-24
4
S
0
3000
17.4617
D
8520
D
Stock Option
5.16
2021-02-24
4
M
0
3000
0.00
D
2029-09-19
Common Stock
3000
89000
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
This option vested and became exercisable as to 25% of the underlying shares of common stock on August 1, 2020 and will become vested and exercisable as to the remainder of the shares in 12 equal quarterly installments thereafter.
/s/ Roni Mamluk, Ph.D., Attorney-in-Fact for Gary B. Gordon
2021-02-26